Compare Enveric Biosciences Inc (ENVB) vs Annaly Capital Management, Inc. (NLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Annaly Capital Management, Inc. — how do they compare? Enveric Biosciences Inc trades at $1.45 (market cap $6.20M), while Annaly Capital Management, Inc. trades at $23.14 (market cap $17.27B). The key difference: Annaly Capital Management, Inc. is far larger — about 2785.5× Enveric Biosciences Inc's market cap, and Annaly Capital Management, Inc. pays a 13.09% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | NLY | |
|---|---|---|
Market Cap | $6.20M | $17.27B |
Sector | Health | Financials |
52-Week High | $17.40 | $24.40 |
52-Week Low | $1.27 | $20.21 |
Enterprise Value | $1.30M | — |
Dividend Yield | — | 13.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.55, down 0.64% with a bullish technical signal despite negative profitability. The company shows promising clinical progress with its lead candidate EB-003, supported by recent FDA guidance and positive preclinical data. While quarterly earnings consistently beat expectations, the company remains unprofitable with negative ROE and ROA. Analyst sentiment is positive with 75% buy ratings.
Investment outlook hinges on successful drug development milestones, with regulatory progress and intellectual property expansion providing catalysts. Key risks include clinical trial outcomes, cash burn from operations, and dependence on financing activities. The stock presents speculative growth potential for risk-tolerant investors focused on biotech innovation.
Annaly Capital Management (NLY) trades at $23.04, up 1.68% today, with a bullish technical outlook and strong earnings momentum after beating Q2 2026 EPS estimates. The stock shows robust fundamentals with a P/E of 5.57, ROE of 20.66%, and a net income margin of 92.77%. Recent news highlights inclusion in Zacks' Strong Buy lists and a focus on high-yield income, supported by a $0.75 dividend payment scheduled for July 2026.
Outlook is positive with analyst consensus favoring Buy ratings (57.15%) and a $24.50 price target, implying ~6% upside. Key risks include interest rate sensitivity and mortgage market volatility, but diversified housing finance strategies and consistent dividend coverage provide stability. Investment appeal centers on value valuation and income generation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Annaly Capital Management, Inc.
Annaly Capital Management Inc is an American mortgage real estate investment trust. The company segments its operations into Residential and Commercial real estate investments. While Annaly's Residential assets are primarily comprised of agency mortgage-backed securities and debentures, it is primarily invested in commercial mortgage loans and mortgage-backed securities in its Commercial unit through its subsidiary, Annaly Commercial Real Estate Group. Agency mortgage-backed securities and debentures make up the majority of the company's overall portfolio. Most of the company's counterparties are located in the U.S. Annaly generates nearly all of its revenue from the spread between interest earned on its assets and interest payments made on its borrowings.
Read more on NLY →
